<DOC>
	<DOCNO>NCT03072199</DOCNO>
	<brief_summary>RITA-MI aim develop novel therapeutic concept target immune response patient acute myocardial infarction ( MI ) deplete B-cells single injection Rituximab approve clinical use cancer , autoimmune disease inflammatory condition . The goal re-purpose drug , translate discovery benefit patient high risk cardiovascular event . Rituximab expect limit infarction size improve heal process , complementary therapeutic strategy . The applicant intend perform clinical study patient acute myocardial infarction ( MI ) . The objective find optimal dose ( low dose high biological efficacy best safety profile ) peripheral blood B cell depletion first 6 day injection , selective molecular signature associate improved heart function analysis peripheral blood sample . The study rationale decrease inflammatory reaction upon tissue necrosis follow heart muscle ischemia .</brief_summary>
	<brief_title>Rituximab Patients With Acute ST-elevation Myocardial Infarction Study</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Age 1875 year old Acute anterior STEMI successful primary percutaneous coronary intervention ( PCI ) stent implantation culprit lesion first 24h onset symptom A previous history STEMI Cardiogenic shock ( systolic blood pressure &lt; 80 mm Hg , unresponsive fluid , necessitate catecholamine ) , electrical instability severe congestive heart failure Corrected QT interval ( QTc ) &gt; 500 msec use Bazett 's formula Hematologic abnormality ( hemoglobin &lt; 10 g/dL hematocrit &lt; 30 % , platelet cell count &lt; 100 x103/μL , white blood cell count &lt; 4 x103/μL ) Renal failure ( estimate GFR MDRD formula &lt; 45 ml/min/1.73m2 ) ; Known hepatic failure abnormal liver function test baseline ( ALT &gt; 2 x ULN ) . Active recurrent hepatitis ( type B ) . Known HIV infection Current previous tuberculosis ( Chest XRay ) Current infection Presence history previous five year ongoing cancer , except situ cancer cervix basal cell carcinoma Any oral intravenous immunosuppressive treatment ( concomitant 100 mg methylprednisolone ) , disease modify drug immune modulatory monoclonal antibody Allergy rituximab one excipients Expected need vaccination live attenuate vaccine study include incomplete vaccination course . Known suspect pregnancy screen lactate woman Women childbearing age unless confirm direct question reproductively sterile postmenopausal Participation clinical trial Inability comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Rituximab</keyword>
	<keyword>B cell</keyword>
</DOC>